| Identification | Back Directory | [Name]
BF844 | [CAS]
1404506-35-9 | [Synonyms]
BF844
BioFocus 844
BF 844
(BioFocus 844)
1H-Pyrazolo[3,4-c]pyridazine-1-ethanol, 4-chloro-α,α-dimethyl-3,5-diphenyl- | [Molecular Formula]
C21H19ClN4O | [MOL File]
1404506-35-9.mol | [Molecular Weight]
378.85 |
| Hazard Information | Back Directory | [Uses]
BF 544 is an pharmaceutical shown to mitigate the effect of hearing loss in Usher syndrome type III mammalian models. | [in vivo]
BF844 shows good penetration into the retina and cochlea in vivo[1].
BF844 (10 mg/kg; i.p.) shows significantly preserves hearing in Tg;KI/KI mice[1]. | Animal Model: | Juvenile mice[1] | | Dosage: | 3, 10 mg/kg (3 mg/kg for P6 (post-natal day 6) mice, 10 mg/kg for P20 (post-natal day 20) mice) | | Administration: | I.p. | | Result: | Showed AUC values were determined to be 1.76 μM.h and 1.98 μM.h. |
| Animal Model: | P30 Tg;KI/KI C57BL/6J mice[1] | | Dosage: | 30 mg/kg | | Administration: | I.p.; daily from P30 to P45 | | Result: | Showed significantly preserves hearing with the median threshold of sound intensity in log scale was 57.5–67.5 dB SPL and about 1,000 times more sensitive hearing compared to untreated controls at P55. |
| Animal Model: | P10 Tg;KI/KI C57BL/6J mice[1] | | Dosage: | 10 mg/kg | | Administration: | I.p.; 10 mg/kg every other day and gradually escalated the dose up to 20 mg/kg at P28. From P30 to P45, mice received 30 mg/kg daily | | Result: | Showd the median threshold of sound intensity in log scale was 55, 42.5 and 37.5 dB SPL lower at 8, 16 and 32 kHz at P55, respectively. |
|
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|